Tuesday, August 28, 2018 1:29:04 AM
Nohura isn't even remotely qualified, he was drummed out of a device mfg and no one else would hire him in San Diego. He would be cutoff during interviews and kicked out of the building. Not even his own supervisor at Targegen wanted him, Ulrich wanted a loudmouth to help him spin their crap and that's exactly what they had.
Sanofi is trying to take legal action for what was done to them.
Pay attention investors, do your research, there are SO MANY talented chemists available from the pharma downturn, why would White pick a no talent, no track record hack like Nohura.
You guys all cry the blues when you get burned by biotech pump and dumps, do a little research on who is installed in key scientific positions.
Recent CLSD News
- Clearside Biomedical Appoints Seasoned Biotechnology Executive Anthony S. Gibney to its Board of Directors • GlobeNewswire Inc. • 04/16/2024 11:05:00 AM
- Clearside Biomedical to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference • GlobeNewswire Inc. • 04/02/2024 11:05:00 AM
- Clearside Biomedical Appoints Victor Chong, M.D., MBA as Chief Medical Officer • GlobeNewswire Inc. • 03/18/2024 11:05:00 AM
- Clearside Biomedical Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update • GlobeNewswire Inc. • 03/12/2024 08:05:00 PM
- Clearside Biomedical to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update on Tuesday, March 12, 2024 • GlobeNewswire Inc. • 02/29/2024 12:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/08/2024 10:05:05 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 02/08/2024 09:52:44 PM
- Clearside Biomedical Announces Pricing of $15 Million Registered Direct Offering • GlobeNewswire Inc. • 02/07/2024 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/01/2024 09:01:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/19/2024 11:25:35 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 01/19/2024 08:04:42 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/28/2023 09:10:07 PM
- Clearside Biomedical Reports Significant Progress in ODYSSEY Phase 2b Trial of CLS-AX in Wet AMD • GlobeNewswire Inc. • 12/14/2023 12:05:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/13/2023 09:30:42 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/13/2023 09:10:13 PM
- Clearside Biomedical Announces Third Quarter 2023 Financial Results and Provides Corporate Update • GlobeNewswire Inc. • 11/13/2023 09:05:00 PM
- Clearside Biomedical to Participate in Fireside Chat at the Stifel 2023 Healthcare Conference • GlobeNewswire Inc. • 11/08/2023 12:05:00 PM
- Clearside Biomedical’s Versatile Suprachoroidal Injection Platform Highlighted in Four Ophthalmic Indications in Clinical Data Presentations at AAO 2023 Annual Meeting • GlobeNewswire Inc. • 11/07/2023 09:20:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/03/2023 04:01:10 PM
- BioCryst and Clearside Biomedical Enter Partnership to Develop Avoralstat for Diabetic Macular Edema Using Clearside’s Proprietary SCS Microinjector® • GlobeNewswire Inc. • 11/03/2023 04:00:00 PM
- Clearside Biomedical Announces Presentations at the American Academy of Ophthalmology 2023 Annual Meeting • GlobeNewswire Inc. • 11/02/2023 11:05:00 AM
- Clearside Biomedical Completes Recruitment in ODYSSEY Phase 2b Clinical Trial of CLS-AX in Wet AMD • GlobeNewswire Inc. • 11/01/2023 11:05:00 AM
- Clearside Biomedical to Report Third Quarter 2023 Financial Results and Provide Corporate Update on Monday, November 13, 2023 • GlobeNewswire Inc. • 10/31/2023 11:05:00 AM
- Clearside Biomedical Positive OASIS and Extension Study Data Presented at The Retina Society 56th Annual Scientific Meeting • GlobeNewswire Inc. • 10/16/2023 11:05:00 AM
- Clearside Biomedical Announces Advancement of XIPERE® in Asia-Pacific for Suprachoroidal Treatment of Uveitic Macular Edema as Partner Arctic Vision Completes Enrollment in Phase 3 Clinical Trial in China • GlobeNewswire Inc. • 10/04/2023 01:00:00 PM
Bantec Reports an Over 50 Percent Increase in Sales and Profits in Q1 2024 from Q1 2023 • BANT • Apr 25, 2024 10:00 AM
Cannabix's Breath Logix Alcohol Device Delivers Positive Impact to Private Monitoring Agency in Montana, USA • BLO • Apr 25, 2024 8:52 AM
Kona Gold Beverages, Inc. Announces Name Change to NuVibe, Inc. and Initiation of Ticker Symbol Application Process • KGKG • Apr 25, 2024 8:30 AM
Axis Technologies Group and Carbonis Forge Ahead with New Digital Carbon Credit Technology • AXTG • Apr 24, 2024 3:00 AM
North Bay Resources Announces Successful Equipment Test at Bishop Gold Mill, Inyo County, California • NBRI • Apr 23, 2024 9:41 AM
Epazz, Inc.: CryObo, Inc. solar Bitcoin operations will issue tokens • EPAZ • Apr 23, 2024 9:20 AM